Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | Director | April 22, 2026 | April 24, 2026 |
| Organon & Co.OGN · Entity 4115 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date April 22, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 2,583 |
Reported balance
After 2026-04-22 transaction · row 1
1 source rowRow 1 · 2026-04-22 · Grant · Acquired 782 · Balance 2,583 |
Organon & Co.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 81,141.133 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 17,857.143 · Balance 81,141.133 F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.
F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 20:38 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043245 · wk-form4_1781555927.xml · derivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.133 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:48 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001739940-26-000029 · wk-form4_1777063690.xml · nonDerivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,583 Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 22:04 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 23,904.382 | $10.04 | $240,000.00 |
DisclosureSEC source: 0001821825-25-000059 · wk-form4_1750111465.xml · derivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,702.657 Underlying: Common Stock · 23,904.382 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 20:32 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004426 · doc4.xml · nonDerivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,801 Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:16 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000071 · wk-form4_1718133372.xml · derivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.816 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 21:14 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 539 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005291 · doc4.xml · nonDerivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,163 Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:57 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036791 · doc4.xml · derivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:05 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 624 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-006486 · doc4.xml · nonDerivative · entry 1 Ozuah Phillip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 624 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 23:40 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 5,640 | $35.46 | $199,994.40 |
DisclosureSEC source: 0001104659-22-071141 · tm2218336-9_4seq1.xml · derivative · entry 1 Ozuah Phillip · CIK 0001859685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,638 Underlying: Common Stock · 5,640 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:41 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022685 · doc4.xml · derivative · entry 1 Ozuah Phillip · CIK 0001859685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.